View Future GrowthCullinan Therapeutics 과거 순이익 실적과거 기준 점검 0/6Cullinan Therapeutics 의 수입은 연평균 -36.3%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 30%의 비율로 증가했습니다. 매출은 연평균 81.8%의 비율로 감소해 왔습니다.핵심 정보-36.27%순이익 성장률-25.84%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률-81.80%자기자본이익률-53.80%순이익률n/a최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesConsensus revenue estimates fall by 10% Apr 30Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst Apr 30Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Receive U.S. Food and Drug Administration Acceptance for New Drug Application for Zipalertinib for Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsApr 30Cullinan Therapeutics, Inc., Annual General Meeting, Jun 16, 2026Apr 29Cullinan Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Apr 28We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash WiselyApr 23Consensus revenue estimates decrease by 39% Mar 17President recently sold US$223k worth of stock Feb 24Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth?Jan 23President recently sold US$99k worth of stock Dec 31Price target increased by 11% to US$28.78 Dec 10Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash MeetingDec 09Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid LeukemiaDec 01Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNov 21Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual MeetingNov 04Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025Oct 27Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025Oct 13Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn SituationOct 10Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung CancerSep 09Cullinan Therapeutics, Inc. Announces Board Changes, Effective August 7, 2025Aug 07Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth IndexJun 30+ 4 more updatesHere's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn SituationJun 21Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical OncologyJun 02Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025May 23Price target decreased by 12% to US$28.25 May 12Cullinan Therapeutics, Inc. to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjogren's Disease in the United StatesApr 30Cullinan Therapeutics, Inc., Annual General Meeting, Jun 12, 2025Apr 28Cullinan Therapeutics, Inc. to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsApr 23Cullinan Therapeutics, Inc. Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978Apr 16Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data Apr 08Consensus revenue estimates fall by 52% Mar 07President recently sold US$107k worth of stock Mar 02Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth PlansFeb 27Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior TherapyJan 29New major risk - Shareholder dilution Jan 16Cullinan Therapeutics: Casting A Wide Net With Their Pipeline Jan 08President recently sold US$100k worth of stock Dec 30Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth PlansNov 20Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024Nov 15Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024Nov 05Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusOct 16Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusSep 17Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusSep 16Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024Sep 14Chief Scientific Officer notifies of intention to sell stock Sep 08Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease Aug 30Independent Director exercised options to buy US$402k worth of stock. Jun 13Checking Into Cullinan Therapeutics Jun 09Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of ZipalertinibJun 02Independent Director exercised options to buy US$2.4m worth of stock. May 24Consensus EPS estimates upgraded to US$3.01 loss May 22Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024May 19Cullinan Therapeutics, Inc. Announces Board ChangesMay 17Chief Scientific Officer notifies of intention to sell stock May 08Consensus revenue estimates increase by 19% May 01Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial OfficerApr 30Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In GrowthApr 23Price target increased by 13% to US$28.71 Apr 17Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in fundingApr 16+ 1 more updateCullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024Mar 15Chief Business Officer notifies of intention to sell stock Jan 24New minor risk - Shareholder dilution Jan 19Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesDec 15Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023Nov 04Price target decreased by 11% to US$25.25 Aug 11New minor risk - Profitability Aug 11Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 TrialAug 04Investor sentiment improves as stock rises 17% Jul 17High number of new and inexperienced directors Jul 01Chief Development Officer notifies of intention to sell stock Jun 10Investor sentiment improves as stock rises 16% Jun 06Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid TumorsMay 28Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin LymphomaJan 25Investor sentiment deteriorated over the past week Dec 21Chief Development Officer notifies of intention to sell stock Dec 02Price target decreased to US$34.00 Nov 16Cullinan Oncology Appoints of David P. Ryan to Its Board of DirectorsNov 03Investor sentiment improved over the past week Oct 26Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development Sep 14Cullinan Oncology grants stock options for 125.7K shares Sep 02Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal OfficerAug 16Insider recently sold US$712k worth of stock Aug 06Chief Business Officer notifies of intention to sell stock Jul 22Chief Business Officer notifies of intention to sell stock Jul 15Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth IndexJun 26Insider recently sold US$1.3m worth of stock Jun 25Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).Jun 24Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In GrowthJun 24President recently bought US$100k worth of stock Jun 08Insider recently sold US$4.0m worth of stock May 18Price target decreased to US$39.25 May 17Forecast to breakeven in 2022 May 14Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.May 13Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022May 02매출 및 비용 세부 내역Cullinan Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGS:CGEM 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-2205418730 Sep 250-2175618530 Jun 250-2075617831 Mar 250-1795515431 Dec 240-1675414330 Sep 240-1445013730 Jun 240-1424813631 Mar 240-1324412731 Dec 230-1534214830 Sep 230-1564513530 Jun 230-1424412031 Mar 230654312031 Dec 220111409230 Sep 220105409230 Jun 220113368531 Mar 220-78327031 Dec 2119-66295830 Sep 2119-61286030 Jun 2119-54245731 Mar 2119-47215131 Dec 200-52174330 Sep 200-2862430 Jun 200-2561931 Mar 200-2161731 Dec 190-21517양질의 수익: CGEM 은(는) 현재 수익성이 없습니다.이익 마진 증가: CGEM는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CGEM은 수익성이 없으며 지난 5년 동안 손실이 연평균 36.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CGEM의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CGEM은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(40.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CGEM는 현재 수익성이 없으므로 자본 수익률이 음수(-53.8%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 00:32종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cullinan Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Julian HarrisonBTIGSamantha Lynn SemenkowCitigroup IncJoshua SchimmerEvercore ISI13명의 분석가 더 보기
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Receive U.S. Food and Drug Administration Acceptance for New Drug Application for Zipalertinib for Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsApr 30
Cullinan Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Apr 28
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash MeetingDec 09
Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid LeukemiaDec 01
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNov 21
Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual MeetingNov 04
Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025Oct 27
Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025Oct 13
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung CancerSep 09
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth IndexJun 30+ 4 more updates
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical OncologyJun 02
Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025May 23
Cullinan Therapeutics, Inc. to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjogren's Disease in the United StatesApr 30
Cullinan Therapeutics, Inc. to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsApr 23
Cullinan Therapeutics, Inc. Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978Apr 16
Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data Apr 08
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior TherapyJan 29
Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024Nov 15
Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024Nov 05
Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusOct 16
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusSep 17
Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusSep 16
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024Sep 14
Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of ZipalertinibJun 02
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in fundingApr 16+ 1 more update
Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024Mar 15
Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesDec 15
Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023Nov 04
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 TrialAug 04
Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid TumorsMay 28
Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin LymphomaJan 25
Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).Jun 24
Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.May 13
